Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ummmmm, so your saying your in the red right now!!!
Poor kitty cat. I’ll come at you head on but obviously your emotional Wreck right now
Your PROFESSIONAL opinion is enlightening to the board. Keep it up. Great opinion you have
The momentum seems to be on WTRH side. Staying positive and if we’re correct. 6 plus will come with ease!
GLTA except Shorty....
They are definitely hurting at this stage. Next week MRNA breaks 100 plus $$$$$$$
GLTA except Shorty
Let’s try to find some TRUE DD to post here. Help slow down the confusion on fact vs fiction.
Unfortunately, there’s not a lot as of late. I’ve emailed the company, I’d advise anyone with questions contacting them.
People selling for beer money!!!!! I’ve been here a while and if I’d sold then I definitely be kicking myself today. Plenty of run left in MRNA in my opinion. My account is $$$$$$ so why would it hurt to watch and see if its goes for another run.
I’m banking on it,,,,,,
GLTA except SHORTY!!!!!
Moderna’s 370% Rally Has Cost Short Sellers $1.5 Billion in 2020
(Bloomberg) -- Those betting against high-flying vaccine developer Moderna Inc. have taken their lumps this year with the biotech’s 370% rally costing short sellers almost $1.5 billion, according to financial analytics firm S3 Partners.
The Cambridge, Massachusetts-based biotech has boomed into a $36 billion behemoth amid excitement for its vaccine to treat the novel coronavirus. Still, even with the stock’s parabolic move this week, it’s primed for a squeeze with short investor losses potentially outweighing overbought price conviction, S3 Partners managing director Ihor Dusaniwsky said in a note.
Moderna surged 6.9% to a record on Wednesday after early results from its Covid-19 vaccine candidate drew Wall Street praise. With the company set to start a final-stage study of the vaccine this month, excitement for the company and nerves for short sellers could push the stock even higher.
“There is $2.4 billion of buy-to-cover dry powder in this stock, once shorts begin to cover in size the buying pressure will jolt the stock price suddenly higher,” Dusaniwsky wrote Friday. Roughly 10% of Moderna shares available for trading are currently sold short, according to data compiled by S3 Partners.
The biotech’s 13% rally Friday, alongside peers, fueled it to a new record ahead of detailed results from a trial of AstraZeneca Plc and University of Oxford’s vaccine that are expected Monday. Moderna’s current five-day winning streak which has seen the stock jump by more than 50% is its best such move since April.
Great day WTRH $$$$$$$$
Agreed
Have a great weekend my friend
Stay safe
100 plus next week?????? Any thoughts?
94.86 $$$$$$$
95 printed a couple of times!!!!
Great day MRNA
HONG KONG, July 17 (Reuters) - A Gilead Sciences medicine containing Remdesivir has received a conditional greenlight to be used to curb the coronavirus pandemic, Hong Kong officials said on Friday.
The Hong Kong unit of the California-based drugmaker has to continue to submit additional data on the safety, effectiveness and quality of Veklury, which contains Remdesivir, the Drug Office of Department of Health said on its website.
Remdesivir, which helped shorten hospital recovery times in a U.S. clinical trial, has been added to several countries' list of treatments against the disease that has killed over half a million people globally. (Reporting by Twinnie Siu Hong Kong, Roxanne Liu in Beijing; Editing by Catherine Evans
I’ll be happy 90 plus on a Friday $$$$$
It’s possible.... after MRNA surged past 90 and held we’re on a New level of next leg up!
Let’s keep it up
WTRH strong $$$$$$
$$$$$$$$$$$$$$$$$$$$$
Keep shorting. You’ll get it eventually hahahahaha
MRNA to da MOON $$$$$$$$$$
BRUSSELS (Reuters) - The European Union is negotiating advance purchase deals of potential COVID-19 vaccines with drugmakers Moderna, Sanofi and Johnson & Johnson and biotech firms BioNtech and CureVac, two EU sources told Reuters.
The talks follow a deal reached in June by four EU states with AstraZeneca for the upfront purchase of 400 million doses of its potential COVID-19 vaccine, in principle available to all 27 EU nations.
SCROLL TO CONTINUE WITH CONTENTAd
How He Made $2.8M Trading Stocks Part-Time At Home
RagingBull
How He Made $2.8M Trading Stocks Part-Time At Home
Kyle Dennis took a leap of faith and decided to invest his savings of $15K in the stock market — $2.8M later, he owes his success to these strategies
LEARN MORE
The information on the ongoing talks was shared by the European Commission, the EU executive arm, with EU health ministers at a meeting in Berlin on Thursday, the sources said.
The multiple talks confirm the bloc's more assertive stance on procuring potential COVID-19 shots and drugs after Washington's early moves in securing promising treatments and vaccines.
"We are in talk with several companies on possible COVID-19 vaccines," a spokesman for the EU Commission told Reuters on Friday, declining to comment on specific firms as negotiations were confidential.
More than 150 possible vaccines are being developed and tested around the world to try to stop the pandemic. Of 23 in human clinical trials, at least three are in final Phase III testing - including candidates from China's Sinopharm and Sinovac Biotech and AstraZeneca and Oxford University.
The most advanced EU talks appear to be those with Johnson & Johnson and Sanofi, confirming a Reuters report in June, because the EU is already discussing details on the number of doses needed.
With U.S. giant Johnson & Johnson, the European Union is negotiating a supply of 200 million doses of its potential vaccine, the sources said, adding that additional supplies may also be available.
'ADVANCED TALKS'
The bloc is also planning to secure in the second half of next year 300 million doses of the potential vaccine developed by France's Sanofi in cooperation with British drugmaker GlaxoSmithKline Plc, the sources said.
Asked about the negotiations, Sanofi told Reuters it was in "advanced talks with the EU for the delivery of 300 million doses".
Negotiations were also ongoing, sources said, with U.S. firm Moderna, whose experimental COVID-19 vaccine showed this week it was safe and provoked immune responses in all 45 healthy volunteers in an ongoing early-stage study, according to U.S. researchers.
The bloc is also in talks with German biotechnology firms BioNtech and CureVac to buy in advance their potential vaccines, the sources said. Both firms, which have already been offered EU funds to develop their shots, declined to comment.
BioNtech is developing a potential COVID-19 vaccine in cooperation with U.S. pharmaceutical giant Pfizer, for which 100 million doses could be available by the end of the year.
CureVac is a pioneer in the so-called messenger RNA approach, which is also being pursued by BioNTech and Moderna.
RNA molecules are single-stranded versions of the DNA double-helix that can be produced in a relatively simple biochemical process.
The EU-led talks are conducted by negotiators selected by a steering group in which all 27 EU states are represented.
Once deals are struck, EU states can place orders with drugmakers to secure precise amounts for their populations.
If doses of successful vaccines were not sufficient to cover the whole EU population, shots would be distributed based on demographic and epidemiological data, the Commission has repeatedly said.
A third EU source said the bloc was also renegotiating the deal struck with AstraZeneca by Germany, France, Italy and the Netherlands, to make sure all EU states had equal access to the doses secured in the initial deal.
The source said this discussion was backed by the four states which first signed the deal.
Moderna (MRNA) closed at $81.81 in the latest trading session, marking a +1.98% move from the prior day. This move outpaced the S&P 500's daily loss of 0.34%. At the same time, the Dow lost 0.5%, and the tech-heavy Nasdaq lost 0.73%.
Coming into today, shares of the biotechnology company had gained 26.71% in the past month. In that same time, the Medical sector gained 5.8%, while the S&P 500 gained 5.71%.
Wall Street will be looking for positivity from MRNA as it approaches its next earnings report date. The company is expected to report EPS of -$0.39, up 4.88% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $24 million, up 83.49% from the year-ago period.
SCROLL TO CONTINUE WITH CONTENTAd
Rags To Riches Trader Jeff Bishop Shares His Picks
RagingBull
Rags To Riches Trader Jeff Bishop Shares His Picks
Jeff Bishop Went From Rags To Riches And Made Millions Trading Stocks And Options From Home. He's Now Helping Others By Sharing His Top Picks.
LEARN MORE
For the full year, our Zacks Consensus Estimates are projecting earnings of -$1.50 per share and revenue of $134.67 million, which would represent changes of +3.23% and +123.67%, respectively, from the prior year.
Any recent changes to analyst estimates for MRNA should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.65% lower. MRNA currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 75, which puts it in the top 30% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Hahahahaha!!!!! I luv your honesty $$$$
Read closely... your opinions conflict the report.
Moderna (MRNA) closed at $81.81 in the latest trading session, marking a +1.98% move from the prior day. This move outpaced the S&P 500's daily loss of 0.34%. At the same time, the Dow lost 0.5%, and the tech-heavy Nasdaq lost 0.73%.
Coming into today, shares of the biotechnology company had gained 26.71% in the past month. In that same time, the Medical sector gained 5.8%, while the S&P 500 gained 5.71%.
Wall Street will be looking for positivity from MRNA as it approaches its next earnings report date. The company is expected to report EPS of -$0.39, up 4.88% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $24 million, up 83.49% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$1.50 per share and revenue of $134.67 million, which would represent changes of +3.23% and +123.67%, respectively, from the prior year.
Any recent changes to analyst estimates for MRNA should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.65% lower. MRNA currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 75, which puts it in the top 30% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
We broke 4 again today!!!!!!! Nice work WTRH longs$$$$$$
Why Is Moderna Already Making Coronavirus Vaccine Doses?
The company's preparing to ship a product that hasn't even begun late-stage testing.
Cory Renauer
Cory Renauer
(TMFang4apples)
Jul 16, 2020 at 1:38PM
Author Bio
The race to develop a coronavirus vaccine is moving forward rapidly, and some drugmakers have taken an unusual step to rapidly deploy their respective vaccines the moment the Food and Drug Administration gives the green light. Moderna (NASDAQ:MRNA) is the latest drugmaker to begin manufacturing millions of doses of its still-experimental vaccine, mRNA-1273, at risk.
During a recent conference call to discuss encouraging phase 1 trial results for mRNA-1273, CEO Stephane Bancel sketched out a plan to produce enough doses to vaccinate everybody in the U.S. In fact, the company thinks it can produce between 500 million and 1 billion doses annually. At the moment, Moderna and its manufacturing partners are producing doses of mRNA-1273 at three sites for the U.S. market.
Vials labeled as containing cronavirus vaccine and a stack of cash.
IMAGE SOURCE: GETTY IMAGES.
During a phase 1 clinical trial, all 45 patients had antibodies in their bloodstream produced in response to mRNA-1273. But the immune system produces lots of different antibodies when it encounters anything foreign, so unfortunately it's hard to draw any meaningful conclusions from the results.
Volunteers vaccinated with mRNA-1273 produced high levels of some antibodies also seen in patients that have recovered from COVID-19. But we still have no idea whether or not high concentrations of those antibodies will effectively prevent SARS-CoV-2 from spreading.
By the end of July, Moderna plans to begin a 30,000-patient phase 3 study with mRNA-1273 that was previously scheduled to begin on July 9. The pivotal study was delayed because the company was late to submit final protocol changes to the FDA. The delay puts mRNA-1273 behind AZD1222 from AstraZeneca (NYSE:AZN), another coronavirus vaccine candidate that began a 5,000-patient phase 3 trial in Brazil at the end of June.
Higher highs!!!! Yes sir
Next leg up approaching $$$$$$$$
$$$$$$$$$$$$$$$$$$$
Lots of NEW eyes are upon us my friend.
Welcome all newbies to the MRNA board!!!!
We are setting up nicely yet again and looking forward to reading some phenomenal DD $$$$$$$
GLTA except SHORTY......
Galaxy Next Generation Inc (GAXY)
0.0044 +0.0009 (+25.71%) 07/15/20 [OTC US]
for Wed, Jul 15th, 2020
GO TO:
Projection Effective Date: Jul 16th, 2020
Pivots Stochastics Fibonacci Moving Averages Highs/Lows RSI HLC
SUPPORT/RESISTANCETURNING POINTS
Support/Resistance Levels Price
52-Week High 2.8400
14 Day RSI at 80% 0.0146
14 Day RSI at 70% 0.0084
13-Week High 0.0075
Pivot Point 2nd Level Resistance 0.0069
1-Month High 0.0067
High 0.0060
Pivot Point 1st Resistance Point 0.0056
Last 0.0044
Low 0.0039
Previous Close 0.0035
Pivot Point 1st Support Point 0.0035
Pivot Point 2nd Support Point 0.0027
52-Week Low 0.0022
13-Week Low 0.0022
1-Month Low 0.0022
14 Day RSI at 20% 0.0000
14 Day RSI at 30% 0.0000
What happened
Shares of Waitr Holdings (NASDAQ:WTRH) briefly popped as much as 13% in early trading after the company said it completed a previously announced stock offering. The stock has since given back much of those gains and is up 2% as of 12:40 p.m. EDT.
So what
The offering was an at-the-market (ATM) deal, meaning Waitr sold newly issued shares at prevailing market prices. The regional food delivery tech company issued nearly 23.7 million shares between March 20 and July 10, raising gross proceeds of $48.3 million. Waitr filed for the offering back in March in order to capitalize on its soaring stock price as food delivery platforms have benefited from increased demand during the coronavirus pandemic.
Waitr recently said it would keep hundreds of jobs in the U.S., reversing a previous decision to move positions to Mexico.
Six meals in plastic takeout containers
IMAGE SOURCE: GETTY IMAGES.
"With the completion of our ATM equity offering and the previously announced conversion of a portion of our outstanding debt, we benefit from a strong and flexible balance sheet," CEO Carl Grimstad said in a statement. "As of July 14, 2020, our cash-on-hand was approximately $79 million, which we expect to be further reinforced by the continued momentum and meaningful profitability in our business."
Now what
The company will use $10.5 million of the offering's proceeds to pay down a senior secured term loan, with the rest of the money being used for general corporate purposes and growth initiatives. Based on that prepayment, lenders have agreed to reduce the interest rate on the remaining balance associated with the term loan and convertible notes by 2 percentage points for one year.
That will bring the term loan interest rate down to 5.125% and the convertible notes interest rate down to 4%, and the maturity of both debt instruments will be extended by one year.
Tough few weeks for you I see. Here’s some hope
LONDON (Reuters) - Oil prices fell on Thursday after OPEC and other producers including Russia agreed to ease record supply curbs from August, though the drop was cushioned by tightening global inventories as economic activity picks up.
Brent crude fell 35 cents, or 0.8%, to $43.44 a barrel by 0852 GMT.
SCROLL TO CONTINUE WITH CONTENTAd
How He Made $2.8M Trading Stocks Part-Time At Home
RagingBull
How He Made $2.8M Trading Stocks Part-Time At Home
Kyle Dennis took a leap of faith and decided to invest his savings of $15K in the stock market — $2.8M later, he owes his success to these strategies
LEARN MORE
West Texas Intermediate (WTI) crude was down 49 cents, or 1.2%, to $40.47 per barrel.
Both contracts rose 2% the previous day after a sharp drop in U.S. crude inventories. [EIA/S]
The Organization of the Petroleum Exporting Countries (OPEC) and its allies, known as OPEC+, agreed on Wednesday to scale back oil production cuts from August.
They will reduce their cuts to 7.7 million barrels per day through December from the 9.7 million bpd cuts in place since May.
"Things are getting back to normal on the oil market," said Norbert Rücker, head of economics research at Julius Baer.
"The petro-nations announced the partial lifting of their production restrictions as oil demand rebounds and signs of an easing supply glut emerge... The economic recovery puts demand above supply."
Saudi Arabian Energy Minister Prince Abdulaziz bin Salman said production cuts in August and September would end up amounting to about 8.1 million-8.3 million bpd, more than the headline number.
That is because countries in the grouping which over-produced earlier this year would compensate with extra August-September cuts, he said.
Oil prices are expected to remain boxed in as more supply from OPEC+ countries will likely be absorbed by recovering demand, said Tsutomu Kosuge, president of commodity research firm Marketedge Co.
"I expect Brent will stick to the tight range between $40.50-$46.50 for the next month or so," he said, adding rising tensions between China and the United States may weigh on market sentiment.
International Energy Agency Executive Director Fatih Birol said on Wednesday that global oil markets are slowly rebalancing, with prices of about $40 per barrel expected in coming months.
Good morning #Gaxy#
GLTA today $$$$$
No problem my friend. Listening to opinions vs getting there questions answered directly from the company!!!
No brainer. I’ll be posting my email if or when they respond to my questions
Anyone else please feel free to click on the link to ask about your questions vs listening to all the negative.
Best of trades to all except Shorty!!!!!
https://galaxynext.us/
Link for website if anyone wants to contact the company with there question
Over 250 million bought and traded!!!!!!
Loving this chart today
$$$$$$$$$$$
U as well my friend!
July 15 (Reuters) - Moderna Inc's chief executive said on Wednesday that he expects governments will make the decision on how to allocate COVID-19 vaccines while supplies are scarce.
Chief Executive Stéphane Bancel said on a conference call to discuss early stage clinical results for his company's experimental vaccine that Moderna could potentially work with the Centers for Disease Control and Prevention or the Department of Defense to distribute it in the U.S.
"This is not for a private company to make those decisions. We will not have the right data to be able to make those important decisions," he said. (Reporting by Michael Erman in Maplewood, N.J. and Manas Mishra in Bengaluru; Editing by Chizu Nomiyama)
Testing 4s very soon $$$$$$$
Now a possible cure soon..... airlines will right back where they were $$$$$$$$
Bests of trades to everyone except Shorty!!!!
GREEN premarket $$$$$$$
Plus 13 today $$$$$$$$